Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7UPE

Tau Paired Helical Filament from Alzheimer's Disease not incubated with EGCG

Summary for 7UPE
Entry DOI10.2210/pdb7upe/pdb
Related7UPF
EMDB information26663
DescriptorIsoform Tau-F of Microtubule-associated protein tau (1 entity in total)
Functional Keywordsamyloid, fibril, alzheimer's, disease, protein fibril
Biological sourceHomo sapiens (human)
Total number of polymer chains10
Total formula weight459198.71
Authors
Seidler, P.M.,Murray, K.A.,Boyer, D.R.,Ge, P.,Sawaya, M.R.,Eisenberg, D.S. (deposition date: 2022-04-15, release date: 2022-09-28, Last modification date: 2024-06-12)
Primary citationSeidler, P.M.,Murray, K.A.,Boyer, D.R.,Ge, P.,Sawaya, M.R.,Hu, C.J.,Cheng, X.,Abskharon, R.,Pan, H.,DeTure, M.A.,Williams, C.K.,Dickson, D.W.,Vinters, H.V.,Eisenberg, D.S.
Structure-based discovery of small molecules that disaggregate Alzheimer's disease tissue derived tau fibrils in vitro.
Nat Commun, 13:5451-5451, 2022
Cited by
PubMed Abstract: Alzheimer's disease (AD) is the consequence of neuronal death and brain atrophy associated with the aggregation of protein tau into fibrils. Thus disaggregation of tau fibrils could be a therapeutic approach to AD. The small molecule EGCG, abundant in green tea, has long been known to disaggregate tau and other amyloid fibrils, but EGCG has poor drug-like properties, failing to fully penetrate the brain. Here we have cryogenically trapped an intermediate of brain-extracted tau fibrils on the kinetic pathway to EGCG-induced disaggregation and have determined its cryoEM structure. The structure reveals that EGCG molecules stack in polar clefts between the paired helical protofilaments that pathologically define AD. Treating the EGCG binding position as a pharmacophore, we computationally screened thousands of drug-like compounds for compatibility for the pharmacophore, discovering several that experimentally disaggregate brain-derived tau fibrils in vitro. This work suggests the potential of structure-based, small-molecule drug discovery for amyloid diseases.
PubMed: 36114178
DOI: 10.1038/s41467-022-32951-4
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3.4 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon